{
  "id": 9740766,
  "title": "Citizens reiterates Rezolute stock rating on tumor trial results due",
  "url": "https://urgent.news/2026/09/25/citizens-reiterates-rezolute-stock-rating-on-tumor-trial-results-due",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-25T09:04:50.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/citizens-reiterates-rezolute-stock-rating-on-tumor-trial-results-due-93CH-4916950"
  },
  "original_language": "en",
  "account": "Citizens has reaffirmed a bullish Market Outperform rating and a $11.00 price target for Rezolute (NASDAQ: RZLT) following the presentation of promising tumor-associated hyperinsulinism trial results. The company anticipates delivering top-line revenue from its Phase 3 upLIFT trial, which assesses the efficacy of ersodetug in treating this condition, by the end of 2026. Despite currently trading 66% below its 52-week peak of $11.46, Rezolute's stock has surged 67% year-to-date, with analyst price targets spanning from $4 to $14. The company disclosed fiscal fourth quarter 2026 results and strategic updates, maintaining substantial cash reserves of approximately $108 million, bolstering its ability to complete the tumor-associated hyperinsulinism clinical trials. Citizens' financial health metrics also reveal a robust liquidity position, with a current ratio of 9.68 and more cash than debt on the balance sheet. This favorable outlook stems from a risk-adjusted discounted cash flow model employed by Citizens. Recent discussions with Rezolute's Chief Medical Officer, Dr. Brian Roberts, further emphasize the company's ongoing projects, including positive findings from the open-label extension of their studies and the durability observed in objective tumor-HI responses. These updates come in the wake of the Phase 3 sunRIZE trial, which did not achieve its primary objective, and precede the conclusive upLIFT readout, capturing the attention of investors who will closely monitor these developments.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Citizens reiterates Summit Therapeutics stock rating on trial data",
        "url": "https://urgent.news/2026/09/25/citizens-reiterates-summit-therapeutics-stock-rating-on-trial-data",
        "published": "2026-09-25T09:04:52.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}